Serum thymic factor prevents LPS-induced pancreatic cell damage in mice via up-regulation of Bcl-2 expression in pancreas

被引:19
作者
Saitoh, N
Awaya, A
Sakudo, A
Wook, SS
Saeki, K
Matsumoto, Y
Onodera, T
机构
[1] Univ Tokyo, Sch Agr & Life Sci, Dept Mol Immunol, Bunkyo Ku, Tokyo 1138657, Japan
[2] Japan Sci & Technol Corp, Tokyo 1900012, Japan
关键词
lipopolysaccharide; serum thymic factor; diabetes; apoptosis;
D O I
10.1111/j.1348-0421.2004.tb03471.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The protective effect of synthetic serum thymic factor (FTS) nonapeptide on lipopolysaccharide (LPS)-induced pancreatic cell damage in 10-week-old BALB/c male mice was investigated. Mice were divided into three groups. Group I was treated with LPS (10 mug/head; i.p.) (LPS-treated mice). Group II was administered with FTS (50 mug/head; i.p.) 24 hr before treatment with LPS and complemented immediately before LPS injection with FTS (50 mug/head; i.p.) (FTS-administered mice). Group III was only treated with the same volume of saline (control mice). Treatment of LPS in vivo resulted in the destruction of pancreatic acinar cells. In those cells, many apoptotic cells were detected by immunohistochemistry using an anti-single stranded DNA antibody. Immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR) revealed that LPS treatment also caused low or a lack of insulin expression in pancreatic islets. In contrast, morphological change was not seen and apoptotic cell death was suppressed in pancreatic cells of FTS-administered mice. Moreover, insulin expression was normal in those mice. FTS administration enhanced expression of Bcl-2 mRNA levels in pancreatic tissues and IL-6 mRNA levels in splenocytes significantly compared with those of LPS treatment at 3 hr after LPS injection. These findings suggest that FTS prevents LPS-induced cell damage via enhancing Bcl-2 expression in the pancreas and systemic IL-6 production.
引用
收藏
页码:629 / 638
页数:10
相关论文
共 55 条
[1]   IL-1 produced and released endogenously within human islets inhibits β cell function [J].
Arnush, M ;
Heitmeier, MR ;
Scarim, AL ;
Marino, MH ;
Manning, PT ;
Corbett, JA .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (03) :516-526
[2]   ISOLATION, BIOCHEMICAL CHARACTERISTICS, AND BIOLOGICAL-ACTIVITY OF A CIRCULATING THYMIC HORMONE IN MOUSE AND IN HUMAN [J].
BACH, JF ;
DARDENNE, M ;
PLEAU, JM ;
BACH, MA .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1975, 249 (FEB28) :186-210
[3]  
BACH MA, 1979, J IMMUNOL, V122, P2505
[4]   The microbial product lipopolysaccharide confers diabetogenic potential on the T cell repertoire of BDC2.5/NOD mice: Implications for the etiology of autoimmune diabetes [J].
Balasa, B ;
Van Gunst, K ;
Sarvetnick, N .
CLINICAL IMMUNOLOGY, 2000, 95 (02) :93-98
[5]  
Balasa B, 1997, J IMMUNOL, V159, P4620
[6]   Cytokine-induced apoptosis and necrosis are preceded by disruption of the mitochondrial membrane potential (Δψm) in pancreatic R1Nm5F cells:: prevention by Bcl-2 [J].
Barbu, A ;
Welsh, N ;
Saldeen, J .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2002, 190 (1-2) :75-82
[7]   Treatment with neutralizing antibodies specific for IL-1 beta prevents cyclophosphamide-induced diabetes in nonobese diabetic mice [J].
Cailleau, C ;
DiuHercend, A ;
Ruuth, E ;
Westwood, R ;
Carnaud, C .
DIABETES, 1997, 46 (06) :937-940
[8]   The role of Fas in autoimmune diabetes [J].
Chervonsky, AV ;
Wang, Y ;
Wong, FS ;
Visintin, I ;
Flavell, RA ;
Janeway, CA ;
Matis, LA .
CELL, 1997, 89 (01) :17-24
[9]  
CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
[10]   INTRAISLET RELEASE OF INTERLEUKIN-1 INHIBITS BETA-CELL FUNCTION BY INDUCING BETA-CELL EXPRESSION OF INDUCIBLE NITRIC-OXIDE SYNTHASE [J].
CORBETT, JA ;
MCDANIEL, ML .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (02) :559-568